company background image
OCC logo

Orthocell CHIA:OCC Stock Report

Last Price

AU$1.16

Market Cap

AU$274.0m

7D

19.9%

1Y

178.9%

Updated

17 Dec, 2024

Data

Company Financials

Orthocell Limited

CHIA:OCC Stock Report

Market Cap: AU$274.0m

OCC Stock Overview

A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. More details

OCC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings have declined by 2.4% per year over past 5 years

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$5M)

Volatile share price over the past 3 months compared to the Australian market


My Notes

Capture your thoughts, links and company narrative

Orthocell Limited Competitors

Race Oncology

ASX:RAC

AU$240.4m

Aroa Biosurgery

ASX:ARX

AU$224.2m

Imugene

ASX:IMU

AU$275.2m

PYC Therapeutics

ASX:PYC

AU$676.6m

Price History & Performance

Summary of share price highs, lows and changes for Orthocell
Historical stock prices
Current Share PriceAU$1.16
52 Week HighAU$1.21
52 Week LowAU$0.35
Beta0.87
1 Month Change82.28%
3 Month Change157.22%
1 Year Change178.92%
3 Year Change131.50%
5 Year Change141.15%
Change since IPO212.84%

Recent News & Updates

Recent updates

Shareholder Returns

OCCAU BiotechsAU Market
7D19.9%-0.8%-1.0%
1Y178.9%3.9%9.8%

Return vs Industry: OCC exceeded the Australian Biotechs industry which returned 3.7% over the past year.

Return vs Market: OCC exceeded the Australian Market which returned 10% over the past year.

Price Volatility

Is OCC's price volatile compared to industry and market?
OCC volatility
OCC Average Weekly Movement13.8%
Biotechs Industry Average Movement9.4%
Market Average Movement8.1%
10% most volatile stocks in AU Market16.9%
10% least volatile stocks in AU Market3.1%

Stable Share Price: OCC's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: OCC's weekly volatility has increased from 9% to 14% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006n/aPaul Andersonorthocell.com

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. The company offers Ortho-ATI, a cell therapy for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; Remplir, a collagen scaffold used in peripheral nerve repair; and Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

Orthocell Limited Fundamentals Summary

How do Orthocell's earnings and revenue compare to its market cap?
OCC fundamental statistics
Market capAU$273.98m
Earnings (TTM)-AU$7.18m
Revenue (TTM)AU$5.32m

51.5x

P/S Ratio

-38.2x

P/E Ratio

Is OCC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OCC income statement (TTM)
RevenueAU$5.32m
Cost of RevenueAU$1.63m
Gross ProfitAU$3.69m
Other ExpensesAU$10.87m
Earnings-AU$7.18m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.03
Gross Margin69.39%
Net Profit Margin-135.10%
Debt/Equity Ratio0%

How did OCC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 02:49
End of Day Share Price 2024/12/17 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Orthocell Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tara SperanzaBell Potter